Streptococcus pneumoniae in vitro development of resistance to amoxicillin/clavulanic acid, cefaclor, levofloxacin and azithromycin
作者： Laura M Koeth , Caryn E Good , Kay A Saunders , Charles Jakielaszek
DOI: 10.1016/J.IJANTIMICAG.2003.12.016
关键词: Cefaclor 、 Levofloxacin 、 Amoxicillin 、 Antibacterial agent 、 Streptococcus pneumoniae 、 Microbiology 、 Ofloxacin 、 Clavulanic acid 、 Medicine 、 Amoxicillin/clavulanic acid
摘要: The purpose of this study was to determine effect repeated exposure sub-inhibitory concentrations amoxicillin/clavulanic acid on the development resistance in Streptococcus pneumoniae. Other agents, azithromycin, cefaclor and levofloxacin, were also tested. Twenty S. pneumoniae passaged for 9 days presence each antimicrobial agent MICs determined by NCCLS macro-dilution method. There a four-fold increase 2 20 isolates. Three tested against cefaclor, 11 13 azithromycin levofloxacin showed ≥4-fold increase. Amoxicillin/clavulanic most stable agents Cefaclor fairly stable. Azithromycin affected.
elsevier.com
sci-hub.se 参考文章(18)
Mary Jane. Ferraro, Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically NCCLS. ,(2000)
Todd A. Davies, Glenn A. Pankuch, Bonifacio E. Dewasse, Michael R. Jacobs, Peter C. Appelbaum, In Vitro Development of Resistance to Five Quinolones and Amoxicillin-Clavulanate in Streptococcus pneumoniae Antimicrobial Agents and Chemotherapy. ,vol. 43, pp. 1177- 1182 ,(1999) , 10.1128/AAC.43.5.1177
Erika Bruck, National Committee for Clinical Laboratory Standards. Pediatrics. ,vol. 65, pp. 187- 188 ,(1980)
Nicole J. Johnston, Joyce C. de Azavedo, James D. Kellner, Donald E. Low, Prevalence and characterization of the mechanisms of macrolide, lincosamide, and streptogramin resistance in isolates of Streptococcus pneumoniae. Antimicrobial Agents and Chemotherapy. ,vol. 42, pp. 2425- 2426 ,(1998) , 10.1128/AAC.42.9.2425
C Janoir, V Zeller, M D Kitzis, N J Moreau, L Gutmann, High-level fluoroquinolone resistance in Streptococcus pneumoniae requires mutations in parC and gyrA. Antimicrobial Agents and Chemotherapy. ,vol. 40, pp. 2760- 2764 ,(1996) , 10.1128/AAC.40.12.2760
Emilio Pérez-Trallero, José M. Marimon, Luis Iglesias, Julián Larruskain, Fluoroquinolone and macrolide treatment failure in pneumococcal pneumonia and selection of multidrug-resistant isolates. Emerging Infectious Diseases. ,vol. 9, pp. 1159- 1162 ,(2003) , 10.3201/EID0909.020810
Clyde Thornsberry, D.F. Sahm, Antimicrobial Resistance in Respiratory Tract Pathogens: Results of an International Surveillance Study Chemotherapy. ,vol. 46, pp. 15- 23 ,(2000) , 10.1159/000048488
Ross Davidson, Rodrigo Cavalcanti, James L. Brunton, Darrin J. Bast, Joyce C.S. de Azavedo, Pamela Kibsey, Christine Fleming, Donald E. Low, Resistance to Levofloxacin and Failure of Treatment of Pneumococcal Pneumonia The New England Journal of Medicine. ,vol. 346, pp. 747- 750 ,(2002) , 10.1056/NEJMOA012122
Laura M Koeth, Michael R Jacobs, Saralee Bajaksouzian, Anne Zilles, Gengrong Lin, Peter C Appelbaum, Comparative in vitro activity of gemifloxacin to other fluoroquinolones and non-quinolone agents against Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis in the United States in 1999-2000. International Journal of Antimicrobial Agents. ,vol. 19, pp. 33- 37 ,(2002) , 10.1016/S0924-8579(01)00431-9
DJ Hoban, GV Doern, AC Fluit, M Roussel-Delvallez, RN Jones, None, Worldwide Prevalence of Antimicrobial Resistance in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the SENTRY Antimicrobial Surveillance Program, 1997–1999 Clinical Infectious Diseases. ,vol. 32, ,(2001) , 10.1086/320181